Filing Details

Accession Number:
0001562180-20-001123
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-02-12 17:36:19
Reporting Period:
2020-02-10
Accepted Time:
2020-02-12 17:36:19
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1434418 Constellation Pharmaceuticals Inc CNST Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1680329 Emma Reeve C/O Constellation Pharmaceuticals, Inc.
215 First Street, Suite 200
Cambridge MA 02142
Chief Financial Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-02-10 200 $7.60 200 No 4 M Direct
Common Stock Disposition 2020-02-10 200 $35.00 0 No 4 S Direct
Common Stock Acquisiton 2020-02-11 7,212 $7.60 7,212 No 4 M Direct
Common Stock Disposition 2020-02-11 7,212 $35.04 0 No 4 S Direct
Common Stock Acquisiton 2020-02-11 1,430 $8.04 1,430 No 4 M Direct
Common Stock Disposition 2020-02-11 1,430 $35.04 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2020-02-10 200 $0.00 200 $7.60
Common Stock Stock Option (right to buy) Disposition 2020-02-11 1,430 $0.00 1,430 $8.04
Common Stock Stock Option (right to buy) Disposition 2020-02-11 7,212 $0.00 7,212 $7.60
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
28,412 2028-03-05 No 4 M Direct
36,266 2028-04-22 No 4 M Direct
21,200 2028-03-05 No 4 M Direct
Footnotes
  1. This transaction was executed in multiple trades at prices ranging from $35.00 to $35.095. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  2. This option was granted on March 6, 2018. The shares underlying the option are scheduled to vest in equal quarterly installments through December 6, 2021.
  3. This option was granted on April 23, 2018. The shares underlying the option are scheduled to vest in equal quarterly installments through October 23, 2021.